New oral cocktail aims to tame tough leukemia

NCT ID NCT05360160

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new all-oral combination of three drugs—SNDX-5613, ASTX727, and venetoclax—for people with acute myeloid leukemia (AML) or related leukemia. The first part finds the safest dose of SNDX-5613, and the second part checks if that dose helps control the disease. About 43 participants aged 12 and older with specific genetic types of AML are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SNDX-5613 (menin inhibitor) combined with decitabine/cedazuridine (ASTX727) and venetoclax
What this could lead to: If successful, this could offer a new oral treatment option for certain types of AML, potentially improving disease control and survival.
What could go wrong: This is an early-phase trial with only 43 participants, so results may not apply broadly. Side effects from the drug combination are unknown, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia mixed phenotype acute leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.